Urologix Inc. (ULGX)
Signing of an Exclusive Worldwide License for the Prostiva RF Therapy System for BPH Conference Call
September 6, 2011 10:30 AM ET
Stryker Warren, Jr. – CEO
Greg Fluet – EVP and COO
Brian Smrdel – CFO
Ernest Andberg – Feltl and Company
Good afternoon ladies and gentlemen, and welcome to the Urologix Conference Call to discuss the signing of an exclusive worldwide license for the Prostiva RF Therapy System from Medtronic, Inc. At this time, all participants are in a listen-only mode. As a reminder, this conference is being recorded and will be available for replay on the Company's website, www.urologix.com, under the Investor Relations section after the completion of this call.
Certain information discussed during this conference call, including answers to your questions, may contain forward-looking statements that are made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, believe, anticipate, estimate, or continue, or comparable terminology, are intended to identify forward-looking statements. Actual results may differ materially from those stated or implied in any forward-looking statements due to risks and uncertainties. A detailed discussion of risks and uncertainties may be found in the press release issued by Urologix today in Urologix’s recent Annual Report on Form 10-K for the year ended June 30, 2010 and other documents filed with the Security and Exchange Commission. Urologix disclaims any obligation to update any forward-looking statements made during the course of this call.
It is now my pleasure to introduce your host, Mr. Stryker Warren, Jr. Chief Executive Officer. Please proceed, sir.